ROVI Laboratorios Farmaceuticos

SP: ROVI

0m market cap

0 last close

Laboratorios Farmacéuticos ROVI is a fully integrated Spanish speciality pharmaceutical company involved in the development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs with a particular expertise in low molecular weight heparin (LMWH).

Investment summary

ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic Spanish market. ROVI is at a major inflection point since obtaining market authorisation for its internally developed enoxaparin biosimilar (Becat) in multiple countries. ROVI has commenced marketing in several European countries and has signed out-licensing agreements that cover 91 countries globally – key drivers for sales and operating growth in the medium term. R&D progress continues with its proprietary ISM technology. Notably, its risperidone ISM (DORIA), a long-acting injectable for schizophrenia, has recently completed a Phase III study, meeting its pre-specified primary endpoint; NDA fillings can be expected by 2019/2020.

Industry outlook

ROVI has a strong presence in the Spanish heparin market (and select international markets through partners), where it has been manufacturing and marketing its flagship product, Hibor (second-generation LMWH), since 1998.

Last updated on
Sector
Healthcare
Share price graph
Key management
Javier Lopez-Belmonte Encina CFO
Marta Campos Martinez Investor Relations